225 related articles for article (PubMed ID: 11772257)
1. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Giembycz MA
Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
Kroegel C; Foerster M
Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
[TBL] [Abstract][Full Text] [Related]
3. Cilomilast.
Schachter EN
Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
[TBL] [Abstract][Full Text] [Related]
4. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Compton CH; Gubb J; Nieman R; Edelson J; Amit O; Bakst A; Ayres JG; Creemers JP; Schultze-Werninghaus G; Brambilla C; Barnes NC;
Lancet; 2001 Jul; 358(9278):265-70. PubMed ID: 11498212
[TBL] [Abstract][Full Text] [Related]
5. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
Martina SD; Ismail MS; Vesta KS
Ann Pharmacother; 2006 Oct; 40(10):1822-8. PubMed ID: 16985092
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
7. PDE4 inhibitors in COPD--a more selective approach to treatment.
Vignola AM
Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033
[TBL] [Abstract][Full Text] [Related]
8. Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.
Baeumer W; Szelenyi I; Kietzmann M
Expert Rev Clin Immunol; 2005 May; 1(1):27-36. PubMed ID: 20477652
[TBL] [Abstract][Full Text] [Related]
9. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Rennard SI; Schachter N; Strek M; Rickard K; Amit O
Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
[TBL] [Abstract][Full Text] [Related]
10. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Giembycz MA
Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of Cilomilast.
Down G; Siederer S; Lim S; Daley-Yates P
Clin Pharmacokinet; 2006; 45(3):217-33. PubMed ID: 16509757
[TBL] [Abstract][Full Text] [Related]
12. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Gamble E; Grootendorst DC; Brightling CE; Troy S; Qiu Y; Zhu J; Parker D; Matin D; Majumdar S; Vignola AM; Kroegel C; Morell F; Hansel TT; Rennard SI; Compton C; Amit O; Tat T; Edelson J; Pavord ID; Rabe KF; Barnes NC; Jeffery PK
Am J Respir Crit Care Med; 2003 Oct; 168(8):976-82. PubMed ID: 12816740
[TBL] [Abstract][Full Text] [Related]
13. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
Grootendorst DC; Gauw SA; Baan R; Kelly J; Murdoch RD; Sterk PJ; Rabe KF
Pulm Pharmacol Ther; 2003; 16(2):115-20. PubMed ID: 12670781
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
15. Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
Murdoch RD; Cowley H; Kelly J; Higgins R; Webber D
Pulm Pharmacol Ther; 2002; 15(6):521-7. PubMed ID: 12493339
[TBL] [Abstract][Full Text] [Related]
16. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers.
Zussman BD; Benincosa LJ; Webber DM; Clark DJ; Cowley H; Kelly J; Murdoch RD; Upward J; Wyld P; Port A; Fuder H
J Clin Pharmacol; 2001 Sep; 41(9):950-8. PubMed ID: 11549099
[TBL] [Abstract][Full Text] [Related]
17. The next generation of PDE4 inhibitors.
Huang Z; Ducharme Y; Macdonald D; Robichaud A
Curr Opin Chem Biol; 2001 Aug; 5(4):432-8. PubMed ID: 11470607
[TBL] [Abstract][Full Text] [Related]
18. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Ouagued M; Martin-Chouly CA; Brinchault G; Leportier-Comoy C; Depincé A; Bertrand C; Lagente V; Belleguic C; Pruniaux MP
Pulm Pharmacol Ther; 2005; 18(1):49-54. PubMed ID: 15607127
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]